Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia.
Kids Rehab, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
Dev Med Child Neurol. 2019 Mar;61(3):315-321. doi: 10.1111/dmcn.14088. Epub 2018 Oct 31.
To determine the efficacy of interventions for the management of pain in children and adolescents with cerebral palsy (CP).
Electronic databases were searched from the earliest date possible to April 2018 using a mixture of subject headings and free text. Inclusion criteria comprised of studies with (1) diagnosis of CP, (2) under the age of 18 years, (3) intervention for the management of pain, (4) outcome measure of pain, and (5) studies published in English-language peer-reviewed journals.
Fifty-seven studies met the eligibility criteria. Pain related to (n=number of studies): hypertonia (n=17), spastic hip disease (n=13), procedures for the management of CP (n=7), postoperative (n=18), and other (n=2). Most of the studies were of level III to level V evidence.
There is level II evidence to support intrathecal baclofen therapy for pain secondary to hypertonia in spastic and spastic-dyskinetic CP, and non-pharmacological interventions for procedural pain and pharmacological interventions for postoperative pain. Most studies were restricted by retrospective design and limited use of validated outcome measures. Future research is needed to explore multidisciplinary interventions for chronic pain and pain secondary to dystonia. Clinicians and researchers would benefit from a standardized approach to pain assessment.
The strongest evidence exists for pharmacological treatments for postoperative pain in children and adolescents with cerebral palsy (CP). There is moderate evidence for the efficacy of intrathecal baclofen for pain related to hypertonia in predominately spastic CP. There is a lack of standardization in the assessment of pain. There is limited evidence for multimodal and non-pharmacological strategies in paediatric CP.
评估干预措施治疗脑瘫(CP)儿童和青少年疼痛的疗效。
通过主题词和自由文本混合的方式,从最早的时间点开始检索电子数据库,检索时间截至 2018 年 4 月。纳入标准包括:(1)CP 诊断;(2)年龄 18 岁以下;(3)针对疼痛管理的干预措施;(4)疼痛结局测量;(5)以英文发表的同行评议期刊研究。
57 项研究符合入选标准。与疼痛相关的研究内容包括:(1)张力亢进(n=17);(2)痉挛性髋疾病(n=13);(3)CP 管理程序(n=7);(4)术后(n=18);(5)其他(n=2)。大多数研究的证据水平为 III 级至 V 级。
有 II 级证据支持鞘内注射巴氯芬治疗痉挛型和痉挛性运动障碍型 CP 继发于张力亢进的疼痛,非药物干预用于治疗程序相关疼痛,药物干预用于治疗术后疼痛。大多数研究受到回顾性设计和有限使用验证结局测量的限制。需要进一步研究来探索针对慢性疼痛和继发于肌张力障碍的疼痛的多学科干预措施。临床医生和研究人员将受益于疼痛评估的标准化方法。
对于脑瘫(CP)儿童和青少年的术后疼痛,最强的证据是药物治疗。鞘内注射巴氯芬治疗主要为痉挛型 CP 相关张力亢进性疼痛的疗效具有中等证据。疼痛评估缺乏标准化。多模式和非药物策略在儿科 CP 中证据有限。